Nautilus Biotechnology (NAUT) Q4 2024 earnings summary

Executive summary

• Platform launch delayed to late 2026 to reduce technical risk and maximize performance, with a focus on both broad-scale discovery and targeted proteoform detection modalities.

• Key 2024 achievements include improvements in reagent production, assay development, and software for single molecule protein analysis, and the first quantitative measurement of tau proteoforms linked to Alzheimer's Disease.

• Early access for tau proteoform studies planned for first half of 2025, with partnership agreements targeted in the same period.

• Strategic collaborations established with Genentech, Amgen, MD Anderson Cancer Center, and Buck Institute to validate and expand platform applications.

• The platform leverages machine learning and proprietary reagents to achieve high sensitivity and scale, targeting >95% of the human proteome and addressing unmet needs in drug discovery, diagnostics, and precision medicine.

Financial highlights

• Q4 2024 operating expenses were $20.0 million, flat year-over-year and up $0.9 million sequentially.

• Q4 2024 net loss was $17.6 million, compared to $17.0 million in Q4 2023.

• FY 2024 operating expenses totaled $81.5 million, up 7% from FY 2023.

• FY 2024 net loss was $70.8 million, an 11% increase year-over-year.

• Ended 2024 with $206.3 million in cash, cash equivalents, and investments, down from $264 million at end of 2023.

Outlook and guidance

• Platform commercial launch expected in late 2026, with early access program starting 6–9 months prior.

• FY 2025 operating expenses anticipated to be at or below 2024 levels.

• Cash runway now expected to extend through 2027 following a 16% workforce reduction.

• Key 2025 milestones: tau proteoform studies, data publication, first tau-related partnership, and progress in decoding proteins from complex samples.

• Revenue streams will include partnerships, instrumentation, consumables, service/support, and SaaS.